Evidence map›Paper›PMID 29328912›Full record

ArticleCell2018

BCG Educates Hematopoietic Stem Cells to Generate Protective Innate Immunity against Tuberculosis.

Eva Kaufmann, Joaquin Sanz, Jonathan L Dunn, Nargis Khan, Laura E Mendonça, Alain Pacis, Fanny Tzelepis, Erwan Pernet, Anne Dumaine, Jean-Christophe Grenier and 10 more

2 registry-linked trialsAbstract read
PubMed Publisher
In one paragraph

Article in Cell, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 750 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
750citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05677113 phase2active not recruitingnot on this mapstarted 2023, after this paper: background citation

A Phase II Study of Perioperative QBECO Site Specific Immunomodulator (Qu Biologics®) in Patients With Metastatic Colorectal Adenocarcinoma Within the Liver Undergoing Resection

TypeinterventionalSponsorSunnybrook Health Sciences CentreRan2023 to 2031Enrolled115ConditionsColorectal Cancer, Liver MetastasesArmsQBECO, Placebo
NCT07527247 phase2recruitingnot on this mapstarted 2025, after this paper: background citation

Using AS01 Adjuvant to Improve Immune Response in Older Adults Through Trained Immunity

TypeinterventionalSponsorSingapore General HospitalRan2025 to 2029Enrolled40ConditionsImmune System Responses and Trained Immunity After AS01 Administration, Healthy AdultArmsAS01 adjuvant (0.5 mL intramuscular), YF17D (Stamaril, Sanofi-Pasteur), Placebo (NaCl 09%, 0.5mL)
3 · Its place in the literature

Who cites it

750 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Route of BCG administration determines success.Human vaccines & immunotherapeutics · 2026
    Review
  3. Trained Immunity in Childhood Vaccination.Acta paediatrica (Oslo, Norway : 1992) · 2026
    Review
  4. Monocytes in pneumonia: Functional plasticity and innate memory (Review).International journal of molecular medicine · 2026
    Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Modeling the Exposome in Murine Cardiovascular Disease.JACC. Basic to translational science · 2026
    Review
  15. Article
  16. Article
  17. The theory of the inflammatory ecosystem.Science China. Life sciences · 2026
    Review
  18. Article
  19. Article
  20. mBio · 2026
    Article

690 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors.

Eva KaufmannMeakins-Christie Laboratories, Department of Medicine, Department of Microbiology and Immunology, Department of Pathology, McGill International TB Centre, McGill University Health Centre, Montreal, QC H4A 3J1, Canada.
Joaquin SanzDepartment of Biochemistry, Faculty of Medicine, Université de Montréal, QC H3T 1J4, Canada; Department of Genetics, CHU Sainte-Justine Research Center, Montreal, QC H3T 1C5, Canada.
Jonathan L DunnMeakins-Christie Laboratories, Department of Medicine, Department of Microbiology and Immunology, Department of Pathology, McGill International TB Centre, McGill University Health Centre, Montreal, QC H4A 3J1, Canada.
Nargis KhanMeakins-Christie Laboratories, Department of Medicine, Department of Microbiology and Immunology, Department of Pathology, McGill International TB Centre, McGill University Health Centre, Montreal, QC H4A 3J1, Canada.
Laura E MendonçaMeakins-Christie Laboratories, Department of Medicine, Department of Microbiology and Immunology, Department of Pathology, McGill International TB Centre, McGill University Health Centre, Montreal, QC H4A 3J1, Canada.
Alain PacisDepartment of Biochemistry, Faculty of Medicine, Université de Montréal, QC H3T 1J4, Canada; Department of Genetics, CHU Sainte-Justine Research Center, Montreal, QC H3T 1C5, Canada.
Fanny TzelepisMeakins-Christie Laboratories, Department of Medicine, Department of Microbiology and Immunology, Department of Pathology, McGill International TB Centre, McGill University Health Centre, Montreal, QC H4A 3J1, Canada.
Erwan PernetMeakins-Christie Laboratories, Department of Medicine, Department of Microbiology and Immunology, Department of Pathology, McGill International TB Centre, McGill University Health Centre, Montreal, QC H4A 3J1, Canada.
Anne DumaineDepartment of Genetics, CHU Sainte-Justine Research Center, Montreal, QC H3T 1C5, Canada.
Jean-Christophe GrenierDepartment of Genetics, CHU Sainte-Justine Research Center, Montreal, QC H3T 1C5, Canada.
Florence Mailhot-LéonardDepartment of Genetics, CHU Sainte-Justine Research Center, Montreal, QC H3T 1C5, Canada.
Eisha AhmedMeakins-Christie Laboratories, Department of Medicine, Department of Microbiology and Immunology, Department of Pathology, McGill International TB Centre, McGill University Health Centre, Montreal, QC H4A 3J1, Canada.
Jad BelleDepartment of Physiology, Complex Traits Group, McGill University, Montreal, QC H3G 0B1, Canada.
Rickvinder BeslaDepartment of Immunology, University of Toronto, Toronto, ON M5G 1L7, Canada.
Bruce MazerMeakins-Christie Laboratories, Department of Medicine, Department of Microbiology and Immunology, Department of Pathology, McGill International TB Centre, McGill University Health Centre, Montreal, QC H4A 3J1, Canada.
Irah L KingMeakins-Christie Laboratories, Department of Medicine, Department of Microbiology and Immunology, Department of Pathology, McGill International TB Centre, McGill University Health Centre, Montreal, QC H4A 3J1, Canada.
Anastasia NijnikDepartment of Physiology, Complex Traits Group, McGill University, Montreal, QC H3G 0B1, Canada.
Clinton S RobbinsDepartment of Immunology, University of Toronto, Toronto, ON M5G 1L7, Canada.
Luis B BarreiroDepartment of Genetics, CHU Sainte-Justine Research Center, Montreal, QC H3T 1C5, Canada; Department of Pediatrics, Faculty of Medicine, Université de Montréal, Montreal, QC H3T 1C5, Canada. Electronic address: luis.barreiro@umontreal.ca.
Maziar DivangahiMeakins-Christie Laboratories, Department of Medicine, Department of Microbiology and Immunology, Department of Pathology, McGill International TB Centre, McGill University Health Centre, Montreal, QC H4A 3J1, Canada. Electronic address: maziar.divangahi@mcgill.ca.

Funding

CIHR 232519CIHR 301538CIHR FDN-143273
6 · The paper itself

Abstract

The dogma that adaptive immunity is the only arm of the immune response with memory capacity has been recently challenged by several studies demonstrating evidence for memory-like innate immune training. However, the underlying mechanisms and location for generating such innate memory responses in vivo remain unknown. Here, we show that access of Bacillus Calmette-Guérin (BCG) to the bone marrow (BM) changes the transcriptional landscape of hematopoietic stem cells (HSCs) and multipotent progenitors (MPPs), leading to local cell expansion and enhanced myelopoiesis at the expense of lymphopoiesis. Importantly, BCG-educated HSCs generate epigenetically modified macrophages that provide significantly better protection against virulent M. tuberculosis infection than naïve macrophages. By using parabiotic and chimeric mice, as well as adoptive transfer approaches, we demonstrate that training of the monocyte/macrophage lineage via BCG-induced HSC reprogramming is sustainable in vivo. Our results indicate that targeting the HSC compartment provides a novel approach for vaccine development.

Indexed as

Immunity, InnateImmunologic MemoryTranscriptomeAnimalsCell LineCells, CulturedEpigenesis, GeneticHematopoiesisHematopoietic Stem CellsMiceMice, Inbred C57BLMycobacterium bovisTuberculosisBCGepigenetic reprogrammingmacrophagesmycobacterium tuberculosisstem cellstrained immunity

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.